Press Releases
March 26, 2024
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
March 12, 2024
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on 3/26/24
February 15, 2024
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
February 1, 2024
Panbela Announces Closing of Approximately $9.0 Million Public Offering
January 30, 2024
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
January 29, 2024
Panbela Announces Pricing of Approximately $9.0 Million Public Offering
January 25, 2024
Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer
Exceeding Anticipated Timelines with Accelerated Momentum
- Interim Data Analysis Anticipated in Mid-2024
- Expects Full Enrollment by Q1 2025
January 18, 2024
Panbela Announces Publication of Clinical Data: A New Approaches to Neuroblastoma Therapy Trial
Panbela Announces Publication of Clinical Data Titled:
Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
- A Phase 1 clinical study showed that high dose DFMO treatment in combination with chemotherapy may provide therapeutic benefits to heavily pretreated patients with neuroblastoma.
January 16, 2024
Panbela Announces 1-for-20 Reverse Stock Split Effective 1/18/24
Events & Presentations